{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:04:55Z","timestamp":1790111095198,"version":"4.0.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373981"],"award-info":[{"award-number":["82373981"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015714","name":"Guizhou Science and Technology Corporation Platform Talents Fund","doi-asserted-by":"publisher","award":["[2017]5733-001"],"award-info":[{"award-number":["[2017]5733-001"]}],"id":[{"id":"10.13039\/501100015714","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015714","name":"Guizhou Science and Technology Corporation Platform Talents Fund","doi-asserted-by":"publisher","award":["CK-1130-002"],"award-info":[{"award-number":["CK-1130-002"]}],"id":[{"id":"10.13039\/501100015714","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tips.2026.09.001","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:32:39Z","timestamp":1789619559000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Closing AI drug-regulatory gaps through harmonized oversight"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0850-8592","authenticated-orcid":false,"given":"Surendra","family":"Sarsaiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishuang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihai","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2026.09.001_bb0005","doi-asserted-by":"crossref","DOI":"10.1155\/joch\/5202999","article-title":"A critical review of the FDA\u2019s draft guidance on artificial intelligence in drug and biological product regulation","volume":"2026","author":"Niazi","year":"2026","journal-title":"J. Chem."},{"key":"10.1016\/j.tips.2026.09.001_bb0010","doi-asserted-by":"crossref","first-page":"916","DOI":"10.3390\/ph19060916","article-title":"AI in drug discovery: clinical failures, regulatory reality, and the validation crisis behind the hype","volume":"19","author":"Khairil","year":"2026","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.tips.2026.09.001_bb0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/ph18010047","article-title":"Harnessing the AI\/ML in drug and biological products discovery and development: the regulatory perspective","volume":"18","author":"Mirakhori","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.tips.2026.09.001_bb0020","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3390\/ph18060788","article-title":"The potential of artificial intelligence in pharmaceutical innovation: from drug discovery to clinical trials","volume":"18","author":"Malheiro","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.tips.2026.09.001_bb0025","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/17460441.2026.2624023","article-title":"Learning from the successes and failures of early artificial intelligence (AI) adoption for drug discovery in Big BioPharma","volume":"21","author":"Braddock","year":"2026","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.tips.2026.09.001_bb0030","doi-asserted-by":"crossref","DOI":"10.1002\/wcms.70072","article-title":"Framework: establishing global standards artificial intelligence implementation, methodology, translation drug discovery","volume":"16","author":"Gangwal","year":"2026","journal-title":"Wiley Interdiscip. Rev. Comput. Mol. Sci."},{"key":"10.1016\/j.tips.2026.09.001_bb0035","doi-asserted-by":"crossref","DOI":"10.1093\/jlb\/lsaf028","article-title":"The future of AI regulation in drug development: a comparative analysis","volume":"12","author":"Lenarczyk","year":"2025","journal-title":"J. Law Biosci."},{"key":"10.1016\/j.tips.2026.09.001_bb0040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","article-title":"Artificial intelligence in drug development","volume":"31","author":"Zhang","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2026.09.001_bb0045","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.medj.2024.07.026","article-title":"Accelerating drug discovery, development, and clinical trials by artificial intelligence","volume":"5","author":"Zhang","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.tips.2026.09.001_bb0050","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3390\/ph18091271","article-title":"Artificial intelligence in small-molecule drug discovery: a critical review of methods, applications, and real-world outcomes","volume":"18","author":"Niazi","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.tips.2026.09.001_bb0055","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2026.1870527","article-title":"Artificial intelligence in drug discovery: from algorithmic foundations to clinical translation","volume":"17","author":"Mao","year":"2026","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2026.09.001_bb0060","doi-asserted-by":"crossref","DOI":"10.1007\/s40264-026-01683-5","article-title":"Analytic misjudgment of drug safety evidence and causality: from the Prosecutor\u2019s Fallacy and Simpson\u2019s Paradox to artificial intelligence","author":"Hammad","year":"2026","journal-title":"Drug Saf."},{"key":"10.1016\/j.tips.2026.09.001_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fdsfr.2026.1718379","article-title":"Federating AI-related regulations for human therapeutics: an AI-enabled, continuously updating regulatory intelligence system","volume":"6","author":"Singh","year":"2026","journal-title":"Front. Drug Saf. Regul."},{"key":"10.1016\/j.tips.2026.09.001_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2025.1585180","article-title":"Exploring the ethical issues posed by AI and big data technologies in drug development","volume":"13","author":"Fan","year":"2025","journal-title":"Front. Public Health"},{"key":"10.1016\/j.tips.2026.09.001_bb0075","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.3390\/jcm15051937","article-title":"Clinical trial design and regulatory requirements for artificial intelligence as a medical device: a PRISMA-ScR-guided scoping review of global guidance and evidence (2017-2025)","volume":"15","author":"Shanmugam","year":"2026","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.tips.2026.09.001_bb0080","doi-asserted-by":"crossref","first-page":"24464","DOI":"10.1038\/s41598-026-53058-6","article-title":"Towards convergence of AI and blockchain for personalized medicine in pharmacogenomics","volume":"16","author":"Shaikh","year":"2026","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2026.09.001_bb0085","series-title":"Artificial Intelligence in Phytochemistry","first-page":"179","article-title":"Legal and regulatory implications of AI utilization in drug development","author":"Khalid","year":"2026"},{"key":"10.1016\/j.tips.2026.09.001_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.70226","article-title":"FDA gene therapy approvals (1998-2025): current status, regulatory evolution, and future directions","volume":"66","author":"Oo","year":"2026","journal-title":"J. Clin. Pharmacol."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726002300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614726002300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:08:55Z","timestamp":1790107735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614726002300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":18,"alternative-id":["S0165614726002300"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2026.09.001","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Closing AI drug-regulatory gaps through harmonized oversight","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2026.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}